Why Mira Shares Are Trading Higher Today
Portfolio Pulse from Vaishali Prayag
MIRA Pharmaceuticals Inc. shares rose after announcing promising preclinical data for Ketamir-2, a novel oral Ketamine analog, showing 100% reversal of neuropathic pain. The company plans to submit an IND application to the FDA by December 2024 and aims for human trials by 2025.
September 27, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' stock increased by 8.41% following the announcement of promising preclinical data for Ketamir-2, which showed a 100% reversal of neuropathic pain. The company plans to advance to human trials by 2025.
The announcement of successful preclinical results for Ketamir-2, a key product in MIRA's pipeline, is a significant positive development. The potential of Ketamir-2 to address neuropathic pain with fewer side effects than traditional treatments could lead to increased investor interest and confidence in MIRA's future prospects, driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100